BioSpace News Archive

Event Brought Together Biopharma Executives and Investors from Around the World for Deal Making and Partnering Opportunities

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will release second quarter 2019 financial results on Monday, August 5, 2019 after the close of market

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the management team will participate in the following upcoming investor conferences:

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2019.

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2019.

Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the closing of its initial public offering of 8,050,000 shares of its common stock at a price to the public of $26.00 per share,

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 second quarter financial results on Thursday, August 8, 2019, before the market opens.

Encompass Health Corp. (NYSE: EHC), a national leader in integrated healthcare, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies, today reported its results of operations for the second quarter ended June 30, 2019.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorisation in the European Union (EU).

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that the Company’s shareholders have voted to approve uplisting to a national securities exchange, during its annual shareholder meeting (“meeting”) held on July 24.